Multiplex gene editing is also enabling “off-the-shelf” allogeneic T cell therapies by eliminating endogenous TCRs and MHC molecules, reducing the risk of graft-versus-host disease (GVHD) [390–392]. This evidence concerns the gene HLA-C and graft versus host disease.